Gut Repair Stack
AKA BPC-157 + KPV
Last reviewed 2026-10-30
Our read Opinion
Rising in functional-medicine gut protocols.
Claims made by sellers, clinics and users. Not verified.
Gut lining repair and calmer inflammation for IBS/IBD-type symptoms and 'leaky gut'.
BPC-157 originated from a gastric protein and has gut-repair animal data; KPV has anti-inflammatory effects in colitis models.
Evidence level: Animal studies mostly
No published human trials of this combination. Both are animal-data compounds.
No human trials have tested this combination. Combining compounds can also combine unknown side effects and interactions.
Both are individually compoundable under the Oct 2026 HHS policy (BPC-157 oral; KPV oral/topical) but not as a single combined product.
Statuses change; check the linked primary sources.
Plausible story, animal-level evidence, and real people with IBD should be talking to a GI doctor.
| Field | BPC-157 | KPV |
|---|---|---|
| Type | Research Only | Research Only |
| Regulatory status | Not FDA-approved; no verified marketing authorization | Not FDA-approved; no verified marketing authorization |
| Compounding status | Off Category 2, review pending | Off Category 2, review pending |
| FDA-approved indications | None | None |
| Categories | Healing & repair, GI | GI, Healing & repair |
| Claimed uses |
|
|
| Mechanism | Synthetic pentadecapeptide studied for tissue repair, angiogenesis and nitric-oxide signaling. Proposed mechanisms largely derive from animal and cell experiments. | Lys-Pro-Val is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. In cell and mouse models, PepT1-mediated uptake inhibits inflammatory NF-kappaB and MAPK signaling. |
| Evidence level | Animal studies mostly | Animal studies mostly |
| Evidence / Hype (opinion) | Evidence Hype | Evidence Hype |
| Momentum (opinion) | Rising | Rising |
| Routes | Injection, Oral | Oral, Topical |
| WADA | Prohibited | Verify |
| Where it stands (opinion) | FDA now places BPC-157 in its withdrawn-nomination table, not the active Category 2 table; this is not compounding authorization. WADA 2026 S0 prohibits BPC-157. | Evidence remains preclinical, including mouse colitis models. FDA moved KPV to its withdrawn-nomination table; this is not authorization for compounding. |
| Last reviewed | 2026-10-30 | 2026-10-30 |
| News (30d) | 3 | 0 |
FDA.gov
The agency posted a revised list of bulk drug substances and their compounding categories.
Journal preprint
Authors identify few controlled human studies among largely preclinical literature.
WADA
Testing bodies note an increase in adverse findings involving unapproved peptides.
Information only. Not medical advice. Describing a stack is not a recommendation to combine, obtain or use any compound. Ratings and "Our Take" are editorial opinion. Full disclaimer.